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Introduction 
Overactive bladder (OAB) syndrome is characterized by urinary urgency, with or without 
urgency urinary incontinence, usually accompanied by increased daytime frequency and 
nocturia, in the absence of urinary tract infection (UTI) or other obvious pathology [1]. 
Urgency urinary incontinence is present in approximately one-third of cases [2], but is not 
a prerequisite. However, of all the OAB symptoms, it has the greatest impact on quality of 
life (QoL) [3, 4], and is associated with significantly lower productivity and higher 
healthcare resource utilization [5]. 
 
Oral pharmacotherapy for OAB comprises antimuscarinics and mirabegron, a  
ȕ3-DGUHQRFHSWRUDJRQLVW$QWLPXVFDULQLFVDQGȕ3-adrenoceptor agonists modulate bladder 
function through different molecular pathways; nevertheless, efficacy is similar for both drug 
classes [6]. In clinical practice, antimuscarinics are often initially prescribed; however, 
increasing the dose may exacerbate antimuscarinic adverse events (AEs) such as dry mouth 
and constipation, which may result in treatment discontinuation [7-10]. Analyses of medical 
claims databases indicate that treatment persistence is better with mirabegron vs 
antimuscarinics [11-13]. 
 
A Phase II European dose-finding study (SYMPHONY; NCT01340027) investigating six 
dose combinations of mirabegron with solifenacin compared with monotherapy with 
mirabegron, solifenacin, or placebo, reported that combination therapy demonstrated greater 
efficacy than solifenacin 5 mg alone on change from baseline to end of treatment (EoT) in 
mean volume voided (MVV)/micturition, frequency of micturitions/24h and urgency episodes. 
All combinations were well tolerated compared with the monotherapies or placebo [14]. 
Solifenacin 5 mg combined with mirabegron 25 mg or 50 mg appeared optimal in terms of 
the benefit/risk profile in this study [15]. In addition, in a trial of patients remaining incontinent 
after initial treatment with solifenacin for 4 weeks (BESIDE; NCT01908829), 
solifenacin+mirabegron combination therapy further improved OAB symptoms and was well 
tolerated compared with solifenacin monotherapy [16]. The current study (SYNERGY) 
evaluated the potential of solifenacin 5 mg (the recommended daily starting dose and the 
most widely used dose in clinical practice) in combination with mirabegron 25 mg or 50 mg, 
to deliver superior efficacy to the individual monotherapies with acceptable tolerability, in the 
general OAB population with urinary incontinence.  
 
Patients and Methods 
Study Design 
This was a multinational, multicentre, randomized, double-blind, parallel-group, placebo- 
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and active-controlled Phase III study (NCT01972841), performed in accordance with the 
International Conference on Harmonization, Good Clinical Practice and the Declaration of 
Helsinki. Independent Review Board/Independent Ethics Committee-approved written 
informed consent was obtained from each patient prior to the study. Patients enrolled at 
sites in the US also signed a Health Insurance Portability and Accountability Act (HIPAA) 
authorization form.   
 
Study duration was 18 weeks, comprising a single-blind, 4-week placebo run-in, a 12-
week double-blind treatment period, and a 2-week, single-blind, placebo run-out period 
)LJ63DWLHQWVDJHG\HDUVZKRKDGH[SHULHQFHGV\PSWRPVRIZHW2$%XUJHQF\
XULQDU\IUHTXHQF\DQGLQFRQWLQHQFHIRUPRQWKVZHUHHOLJLEOHIRUVFUHHQLQJ,QSDWLHQWV
with mixed stress/urgency incontinence, urgency incontinence had to be the predominant 
factor as evidenced by diary data and determined by the investigator. Those who recorded 
RQDYHUDJHPLFWXULWLRQVKXUJHQF\HSLVRGHK (grade 3 or 4 on the Patient 
Perception of Intensity of Urgency Scale [PPIUS]/24h [17])DQGLQFRQWLQHQFHHSLVRGHV
over the 7-day micturition diary were eligible for randomization to double-blind treatment in 
a 2:2:1:1:1:1 ratio to daily: 
± Solifenacin 5 mg + mirabegron 25 mg (combination 5+25 mg) 
± Solifenacin 5 mg + mirabegron 50 mg (combination 5+50 mg) 
± Placebo 
± Mirabegron 25 mg 
± Mirabegron 50 mg 
± Solifenacin 5 mg 
 
Exclusion criteria are shown in Table S1.  
 
Efficacy Assessments  
Co-primary efficacy variables were change from baseline to end of treatment (EoT) in 
mean number of incontinence episodes/24h and micturitions/24h, assessed using a 7-day 
electronic micturition diary. Key secondary efficacy variables were change from baseline 
to EoT in MVV/micturition and in patient-reported outcomes (PROs). PROs, which will be 
the subject of a separate manuscript, included change from baseline to EoT in OAB-q 
Symptom Bother score, Health-related Quality of Life (HRQoL) total score, Patient 
Perception of Bladder Condition (PPBC), Treatment Satisfaction-Visual Analogue Scale 
(TS-VAS) and responder analyses. 
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Other secondary efficacy variables derived from the 7-day micturition diary included change 
from baseline at weeks 4, 8, 12 and EoT in: mean number of incontinence episodes/24h, 
micturitions/24h, urgency episodes24h, urgency incontinence episodes/24h and nocturia 
episodes/24h; the percentage of patients (responders) achieving zero incontinence 
episodes/24h at EoT in the last 7 days prior to each visit, micturition frequency normalization 
(<8 episodes/24h) at weeks 4, 8, 12 and EoT; and the number of urgency incontinence 
episodes and nocturia episodes in the 7-day diary. 
 
Safety Assessments 
Safety assessments at each study visit and during the 2-week placebo run-out period 
included frequency of treatment-emergent adverse events (TEAEs), post-void residual 
(PVR) volume (assessed by ultrasound), changes from baseline in laboratory parameters 
and AEs known to be associated with antimuscarinics (including dry mouth, blurred vision, 
constipation and dyspepsia). Cardiovascular AEs and change from baseline in vital signs, 
including vital signs in a subset of patients participating in an ambulatory blood pressure 
monitoring (ABPM) study will be presented in a manuscript focusing on cardiovascular 
results. Cardiovascular and neoplasm events were adjudicated by independent adjudication 
committees. AEs were coded using MedDRA v 16.0 and summarized by System Organ 
Class (SOC) and Preferred Term. TEAEs for urinary retention were also summarized by 
lower level term and treatment group. TEAEs reported by the investigator as increased PVR 
RUXULQDU\UHWHQWLRQZHUHFRGHGWRµ395LQFUHDVHG¶RUµXULQDU\UHWHQWLRQ¶UHVSHFWLYHO\$Q$(
RIDFXWHXULQDU\UHWHQWLRQZDVFRGHGWRWKHORZHUOHYHOWHUPRIµDFXWHXULQDU\UHWHQWLRQ¶XQGHU
WKH3UHIHUUHG7HUPRIµXULQDU\UHWHQWLRQ¶ 
 
Statistical Analysis 
The planned sample size was based on the change from baseline in mean 
micturitions/24h at EoT. Using a 2:1 randomization ratio between combination therapy, 
and monotherapy and placebo treatment arms, 762 patients in each combination therapy 
arm and 381 patients in each of the monotherapy and placebo arms provided 90% power 
to detect a clinically relevant reduction of 0.55 in mean number of micturitions/24h over 
each monotherapy component at a 2-sided significance level of 0.05. A standard deviation 
(SD) of 2.7 was assumed, based on a previous study with solifenacin, mirabegron and 
solifenacin+mirabegron combinations [14]. As combination therapy groups were 
compared vs both monotherapies, the combined power for both tests was at least 81% 
(assuming independence and a similar effect size of the combination groups over each 
monotherapy).  
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Change from baseline to EoT in mean number of incontinence episodes/24h was 
analyzed using a separate stratified rank analysis of covariance (ANCOVA) model for 
each pairwise treatment group difference of interest (e.g., combination treatment vs each 
monotherapy). The stratified rank ANCOVA methodology was used to calculate P values 
for differences between treatment groups. Point estimates and 95% CIs for differences 
between treatment groups were estimated in an ANCOVA model with treatment group, 
sex, age group, previous OAB treatment and geographic region as fixed factors and 
baseline value as a covariate. Due to the different methodology used to calculate non-
parametric P values and parametric 95% CIs for differences between treatment groups, 
there is a chance that a 95% CI includes 0 even though the P value is <0.05 or vice versa.  
Change from baseline to EoT in mean number of micturitions/24h and key secondary 
endpoints were analyzed using an ANCOVA model with treatment group, sex, age group, 
previous OAB treatment and geographic region as fixed factors and baseline value as a 
covariate.  
As there were co-primary and multiple key secondary endpoints and because two 
combination therapy groups were compared vs their monotherapy components, the type 1 
error was controlled at the one-sided 0.025 level by a sequential Bonferroni-based testing 
procedure following the graphical approach proposed by Bretz et al. [18] (Fig. S2). To 
reduce complexity, MVV was the only key secondary variable included in the testing 
procedure. The first statistical comparison was between the combination 5+50 mg and the 
monotherapies for change from baseline to EoT in incontinence episodes/24h. More 
detailed information on the statistical analysis is provided in Table S2. 
 
Results 
Patient Demographics and Baseline Characteristics 
The study was conducted at 435 sites in 42 countries. In general, all treatment arms were 
similar with respect to demographics and baseline characteristics (Table 1). The majority of 
patients were female (77%); most patients were white (80%). There were no major 
differences across treatment groups in baseline values for mean number of incontinence 
episodes/24h (range 3.2 for the combination 5+50 mg group to 3.6 for the solifenacin 5 mg 
group) or mean number of micturitions/24h (range 10.7 for the combination groups to 11.2 
for the mirabegron 50 mg group). MVV ranged from 152 to 159 mL. Duration of OAB 
symptoms was similar across treatment groups (overall mean duration 67 months). Most 
patients (65%) had urgency incontinence only; all other patients had mixed stress/urgency 
incontinence with urgency as predominant factor. Overall, 46% of patients had received 
previous OAB medications; 23% of patients had previously received solifenacin and 4% of 
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patients had previously received mirabegron. Prespecified subgroup analyses showed that 
patients who were previously treated with OAB medication had more urgency incontinence 
only (71%) and less mixed stress/urgency incontinence with urgency as predominant factor 
(29%) than treatment-QDwYHSDWLHQWVDQGUHVSHFWLYHO\ȕ-blockers were used by 
13% of patients prior to the run-in period and by 13% of patients during the double-blind 
period.   
 
A total of 6991 patients were screened, 6275 patients received placebo run-in medication, 
3527 patients were randomized and 3494 (99%) received double-blind treatment. Of 
these, 3398 (96%) patients were included in the SAF and 3308 (94%) in the FAS. Patients 
(n=96) from one site were excluded from the SAF and FAS due to protocol non-
compliance. The primary reasons for discontinuation were AEs or withdrawal by the 
patient (Fig. 1).  
 
Efficacy 
While the combination 5+50 mg group was superior to solifenacin 5 mg for incontinence, 
with a mean (SE) adjusted difference of ±0.20 (0.12) episodes (95% CI: ±0.44, 0.04, 
P=0.033), statistical superiority vs mirabegron 50 mg was not demonstrated; mean (SE) 
adjusted difference of ±0.23 (0.12) episodes (95% CI: ±0.47, 0.01, P=0.052) (Fig. 2A). 
Therefore, the primary objective for the combination 5+50 mg therapy was not met. Because 
the null hypothesis for this test was not rejected, the subsequent hypotheses for mean 
number of micturitions/24h and MVV/micturition could not be tested. Also, no hypothesis 
testing could be performed for the combination 5+25 mg group.  
 
Nonetheless, incontinence episodes/24h at EoT decreased vs baseline for all treatment 
arms. Mean adjusted change from baseline to EoT was greater in the combination groups vs 
monotherapies and placebo (Fig. 2A). In secondary analyses, all active treatment groups 
had greater improvements in incontinence episodes/24h vs placebo (nominal P values all 
less than 0.05), with effect sizes for the combination groups (combination 5+25 mg: ±0.70 
episodes/24h; combination 5+50 mg: ±0.65 episodes/24h) that were substantially higher 
than those obtained with monotherapy (range ±0.37 episodes/24h for mirabegron 25 mg to ±
0.45 episodes/24h for solifenacin 5 mg). 
 
EoT values for micturitions/24h decreased vs baseline for all treatment arms. Adjusted 
change from baseline to EoT was greater in the combination groups vs monotherapies 
(combination 5+50 mg, nominal P values 0.006 and <0.001 vs solifenacin 5 mg and 
mirabegron 50 mg, respectively; combination 5+25 mg, nominal P values 0.040 and 0.001 
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
vs solifenacin 5 mg and mirabegron 25 mg, respectively) and placebo (nominal P values 
<0.05; Fig. 2B). All active treatment groups had greater improvements in mean numbers of 
micturitions/24h vs placebo (nominal P values <0.05). The effect size was similar across 
mirabegron monotherapy groups (25 mg: ±0.36; 50 mg: ±0.39 micturitions/24h) and slightly 
higher for solifenacin 5 mg (±0.56 micturitions/24h). The effect size in the combination 
groups (combination 5+25 mg: ±0.85; combination 5+50 mg: ±0.95 micturitions/24h) 
suggests a fully additive effect of the combined monotherapies.  
 
Sensitivity Analyses of Co-Primary Efficacy Variables 
In sensitivity analyses, change from baseline in the mean number of micturitions/24h and 
incontinence episodes/24h generally showed consistent results with respect to the effect 
size; some exceptions can be found Fig. S3.  
 
Key Secondary Efficacy Variables 
MVV/micturition at baseline was similar across treatment groups. EoT values increased with 
respect to baseline for all treatment arms. The mean adjusted change from baseline to EoT 
was greater in the combination 5+25 mg and 5+50 mg groups (34.84 mL and 39.73 mL, 
respectively) vs solifenacin 5 mg (30.99 mL), mirabegron 25 mg (13.32 mL), mirabegron 50 
mg (21.99 mL), and placebo (8.44 mL) (Fig. 2C).  
 
Improvements in mean adjusted difference in MVV/micturition for the combination 5+50 mg 
vs solifenacin 5 mg and mirabegron 50 mg were 8.75 mL (nominal P=0.005) and 17.74 mL 
(nominal P<0.001), respectively. The combination 5+25 mg group showed an improvement 
of 21.52 mL (nominal P<0.001) vs mirabegron 25 mg and 3.85 mL vs solifenacin 5 mg 
(nominal P>0.05). All active treatment groups except mirabegron 25 mg had improvements 
in MVV/micturition vs placebo with nominal P values less than 0.05. The effect size was 
largest in the combination 5+50 mg (31.29 mL, nominal P<0.001) and smallest in the 
mirabegron 25 mg group (4.88 mL, nominal P=0.178). The effect size in the combination 
groups was close to additive. 
 
Other Secondary Efficacy Variables  
The combination 5+50 mg group was superior to both monotherapy groups at EoT for 
urgency incontinence episodes, urgency episodes and nocturia; effect sizes appeared to be 
additive. The combination 5+25 mg group was superior to mirabegron 25 mg for the same 
variables, except nocturia. In responder analyses at EoT, odds ratios in favour of both 
combinations vs the monotherapy components were shown for the proportion of patients 
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with zero incontinence episodes (Table 2) and those achieving micturition frequency 
normalization (Table 3).    
 
For almost all parameters, differences were significant for combination therapy at week 4, 
and thereafter remained fairly constant vs monotherapy and placebo. All active treatment 
groups had nominal P values <0.05 compared with placebo at all timepoints. More detailed 
data are shown in Table S3/Fig. S4. 
 
A substantially greater effect of both combinations was observed in the prespecified analysis 
of patients who received previous OAB treatment compared with treatment-naïve patients 
(Fig. 3/Table S4). . 
 
Predefined subgroup analysis of mean number of incontinence episodes/24 h showed that 
patients who received previous OAB treatment had a considerably larger effect size on 
combination treatment vs monotherapy than treatment-naïve patients except for the 
comparison of combination 5+25 mg vs mirabegron. In the subgroup of previously treated 
patients the 95% CIs for the differences of combination vs both monotherapy components 
excluded zero, except for the comparison of combination 5+25 mg vs mirabegron. 
Analysis of mean number of micturitions/24 h showed that patients who received previous 
OAB treatment had a more than twice as high effect size of combination treatment vs 
monotherapy than treatment-naïve patients. In previously treated patients the 95% CIs for 
the differences of combination vs both monotherapy components excluded zero, except 
for the comparison of combination 5+25 mg vs solifenacin (-0.81, 0.00).  
 
An analysis of MVV/micturition showed that patients who received previous OAB 
treatment had a much larger effect size of combination treatment vs monotherapy than 
treatment-naïve patients, especially for the comparison with solifenacin (17.13 and 7.46 
mL for the 5+50 mg and 5+25 mg combination groups, respectively, for previously treated 
patients; 1.48 and 0.59 mL for the 5+50 mg and 5+25 mg combination groups, 
respectively, for treatment-naïve patients). In previously treated patients, the 95% CIs for 
the differences of combination vs both monotherapy components excluded zero, except 
for the comparison of combination 5+25 mg vs solifenacin (-1.50, 16.42 mL).  
 
Analysis of mean number of urgency incontinence episodes/24 h showed that patients 
who received previous OAB treatment had a much larger effect size of combination 
treatment compared to monotherapy than treatment-naïve patients, especially for the 
comparison with solifenacin (-0.43 and -0.53 episodes for the 5+50 mg and 5+25 mg 
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combination groups, respectively, for previously treated patients; -0.06 and 0.02 episodes 
for the 5+50 mg and 5+25 mg combination groups, respectively, for treatment-naïve 
patients). Analysis of mean number of urgency episodes (grade 3 or 4)/24 h showed that 
patients who received previous OAB treatment, prior to entering the study, had a 
considerably larger effect size of combination treatment vs monotherapy than treatment-
naïve patients. In previously treated patients, the 95% CIs for the differences of 
combination vs both monotherapy components excluded zero for both urgency 
incontinence episodes and urgency episodes. 
 
Although differences were small, there seemed to be a trend towards slightly higher effect 
sizes for endpoints related to incontinence and urgency (mean number of incontinence 
episodes, mean number of urgency incontinence episodes and mean number of urgency 
episodes) for patients with urgency incontinence at screening compared to patients with 
mixed stress/urgency incontinence with urgency as predominant factor. 
 
PRO data will be presented elsewhere.  
 
Safety 
2YHUDOORISDWLHQWVH[SHULHQFHG7($($VOLJKWO\LQFUHDVHGIUHTXHQF\
of TEAEs was observed in the combination groups vs monotherapies and placebo (Table 4). 
Incidence of TEAEs was lowest in the mirabegron 25 mg group (32%) and highest in the 
combination 5+25 mg group (40%). The frequency of treatment-related TEAEs (as assessed 
by the investigator) was lowest in the mirabegron 25 mg group and highest in the 
combination 5+25 mg group. The majority of TEAEs in all treatment groups were mild or 
moderate in severity. There were no meaningful differences between treatment groups in the 
incidence of TEAEs that led to discontinuation.   
 
Frequency of UTIs was slightly higher in the combination 5+25 mg group compared with 
other treatment groups, in which the frequency was similar to placebo (Table 4). Events 
indicative of urinary retention were reported slightly more frequently in the combination 
groups compared with monotherapy and placebo. Four of these required catheterization, two 
in the combination 5+25 mg and two in the combination 5+50 mg group. Consistent with 
these findings, PVR volume was slightly increased in the combination groups compared with 
solifenacin 5 mg, and the mirabegron monotherapy and placebo groups (Fig. 4). More 
patients in the combination groups experienced a shift towards higher PVR categories. 
There were no notable differences between sexes. The frequency of hypersensitivity 
reactions was similar between groups, and only in the combination 5+25 mg group was it 
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slightly higher than placebo and monotherapies. No increased risk of somnolence was 
identified with combination or monotherapy treatment compared with placebo. Slightly higher 
frequencies were observed for dry mouth, constipation, and dyspepsia in the combination 
groups compared with each monotherapy group (Table 4). 
 
Detailed data on vital signs and cardiovascular AEs results will be presented elsewhere. 
However, in brief, no relevant differences were observed between active treatment groups 
and placebo or between combination therapy and monotherapy in site-based systolic 
blood pressure, diastolic blood pressure and pulse rate. No relevant differences appeared 
to be present between patients using ȕ-blockers vs patients not on ȕ-blockers (data not 
shown). There were no concerns for ECGs and laboratory data, including QTcF interval 
and liver function tests. 
 
Discussion 
In the largest OAB study to date, combination therapy with solifenacin 5 mg+mirabegron 25 
mg and solifenacin 5 mg+mirabegron 50 mg provided improvements in efficacy compared 
with the respective monotherapies, with effect sizes generally consistent with an additive 
effect. Most effects of combination therapy vs monotherapy were observable by week 4 and 
had an additive effect for many parameters. The clinical relevance of the improvements seen 
with combination therapy for several objective OAB outcome measures was also supported 
by the improvements of combination vs monotherapy in the responder analyses. The odds of 
achieving zero incontinence was 31%±50% higher in the combination groups than in the 
respective monotherapy groups and the P values for these odds ratios were statistically 
significant. 
 
Although the combination 5+50 mg group did not achieve a statistically significant effect 
vs mirabegron 50 mg in the primary analysis of one of the co-primary endpoints (change 
from baseline in mean number of incontinence episodes/24h), differences between 
combination 5+50 mg and both solifenacin 5 mg and mirabegron 50 mg showed nominal 
P values <0.05 when expressed as change from baseline in number of episodes reported 
in the 7-day diary. Also, improvements in efficacy of combination therapy were seen vs 
monotherapy for most of the other variables including the co-primary endpoint of mean 
number of micturitions and the key secondary variable of MVV (except for the combination 
5+25 mg vs solifenacin 5 mg). The effect sizes of combination treatment vs placebo in 
general were similar to the sum of the effect sizes observed in the monotherapy groups vs 
placebo, indicating the additive effect of combination therapy on many parameters. 
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Combination 5+50 mg appeared superior to both monotherapies at EoT and most other 
timepoints for urgency incontinence episodes and urgency episodes. Combination 5+25 mg 
appeared superior to mirabegron 25 mg for the same variables. The improvement of 
combination 5+50 mg over monotherapy for nocturia is notable, as improvements for 
nocturia are uncommon. The effect size of ±0.17 vs monotherapy, however, is small and 
may not be clinically relevant. 
 
Consistent with previous clinical studies, the proportion of women in SYNERGY was higher 
than men (ratio 3:1). Randomized patients in SYNERGY had an average of just over three 
incontinence episodes/24h, comparable with just under three incontinence episodes/24h for 
the incontinent patients in the mirabegron monotherapy studies [19]. A total of 46% of 
patients had previously received OAB medication, compared with prior Phase III studies with 
mirabegron monotherapy, in which 50%±60% of patients had previously received OAB 
medication [19]. As previously noted, there was a larger effect size in patients who had 
received prior OAB treatment vs treatment-naïve patients, with nominal 95% CIs excluding 
zero for combinations vs monotherapies for the primary and key secondary endpoints. All 
patients in the BESIDE study had received previous anticholinergic treatment for OAB as 
part of the 4-week solifenacin run-in period [16].  
 
Solifenacin at a dose of 10 mg was not included in SYNERGY. The Phase II dose-finding 
study (SYMPHONY) observed that the efficacy of the 10+25 mg and 10+50 mg 
combinations was only marginally increased above the efficacy of the 5+50 mg 
combination, however this was at the expense of an important increase in antimuscarinic 
side effects in the 10 mg solifenacin combination groups [14]. Therefore it was judged that 
the benefit/risk of 10 mg combinations was unfavourable and these combinations were not 
taken to the Phase III studies, of which SYNERGY is the second. 
 
Only OAB patients with incontinence (wet OAB) were enrolled in SYNERGY, as it is 
expected that combination therapy in clinical practice will be used mostly in highly 
symptomatic patients. Nevertheless, many patients do not experience incontinence. Indeed, 
prior Phase III studies with mirabegron monotherapy included the general OAB population, 
of which approximately two-thirds of patients are not incontinent [2]. In BESIDE, patients 
ZHUHWKRVHUHPDLQLQJLQFRQWLQHQWDIWHUZHHNV¶WUHDWPHQWZLWKVROLIHQDFLQPJDQGZKR
then received additional mirabegron. In support of the efficacy of combination therapy 
demonstrated in SYNERGY, results from BESIDE demonstrated with similar effect sizes that 
combination therapy with solifenacin and mirabegron for 12 weeks statistically significantly 
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reduced both mean daily urgency urinary incontinence episodes and micturition frequency in 
patients who remained incontinent after treatment with solifenacin 5 mg [16].  
 
Differences between patient recruitment and study design in SYNERGY and BESIDE may 
partially explain the differences in the primary outcomes between the two studies, and may 
be clinically relevant in considering how to select patients for combination therapy. It is 
possible that incomplete responders may require more treatment than treatment-naïve 
patients and that combination treatment may therefore be more effective than monotherapy 
in this patient subset. Indeed, at baseline, patients who were previously treated with OAB 
medication had more urgency incontinence only and less mixed stress/urgency incontinence 
with urgency as predominant factor than treatment-naïve patients.  
 
It should be noted that for all OAB compounds the US Food and Drug Administration 
(FDA) historically required all urinary incontinence episodes as the primary outcome. The 
number of urgency urinary incontinence episodes in SYNERGY was very similar to the 
total number of urinary incontinence episodes, signalling that the vast majority of episodes 
were urgency; therefore this element does not materially affect the interpretation of the 
study. For unknown reasons, the effect only for incontinence does not seem to be fully 
additive. A possible mechanism could be that in most, if not all patients with incontinence, 
some degree of decreased urinary sphincter function must be present. This factor is not 
amenable to drug effects, which could perhaps explain the presence of a ceiling effect on 
incontinence.  
 
In SYNERGY, combination therapy demonstrated a similar safety profile to that expected 
for the monotherapy components [19, 20], with no new safety findings. A similar proportion 
of patients discontinued from all groups and the incidence of TEAEs with the combination 
groups (37%±40%) was similar to that in the BESIDE study (36%) [16]. Regarding TEAEs 
of special interest, hypersensitivity, glaucoma, somnolence and blurred vision were 
reported at a similar frequency in the combination groups in SYNERGY vs monotherapy 
groups or placebo, while there was a slightly higher frequency with UTI in the combination 
5+25 mg group vs other groups. All events that could signify a potential risk for urinary 
retention were captured in this study. Events indicative of urinary retention were reported 
slightly more frequently in combination groups vs monotherapy and placebo; however 
most did not require catheterization. Consistent with these findings, PVR was slightly 
increased in the combination groups vs solifenacin 5 mg and mirabegron monotherapy 
groups. Dry mouth, constipation, and dyspepsia were also reported at a slightly higher 
frequency in combination groups vs monotherapy groups and placebo. However, 
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compared with previous solifenacin 5 mg monotherapy studies, where frequencies of dry 
mouth, constipation and dyspepsia were around 10%, 5%, and 1% [20], the frequencies of 
common antimuscarinic side effects were lower in SYNERGY. Since exposures in 
combination groups were very similar to the monotherapies (data not shown), this 
increase may not be the result of a drug interaction between mirabegron and solifenacin. 
Of note, a previous study did appear to suggest the possibility of a drug±drug interaction 
between mirabegron and solifenacin at high doses [21].  
 
In conclusion, in this study of wet OAB patients, who had previously been exposed to 
anticholinergic therapy and those who were treatment naïve, combination therapy with 
solifenacin 5 mg+mirabegron 25 mg and solifenacin 5 mg+mirabegron 50 mg provided 
improvements in efficacy compared with the respective monotherapies, with effect sizes 
generally consistent with an additive effect. Although the primary objective was not met ± 
by a small margin ± it approached statistical significance for one of the coprimary 
endpoints (incontinence episodes/24h, P=0.052) and the nominal P values for the other 
coprimary endpoint (micturitions/24h) were <0.05. In general, the effect size with 
combination 5+50 mg was larger and more pronounced than with combination 5+25 mg 
with no obvious differences in safety profile. The improvements seen with combination 
therapy compared with monotherapy translated into significant improvements in responder 
rates, supporting the clinical relevance of the effect. Solifenacin+mirabegron combination 
therapy once daily for 12 weeks had an acceptable safety profile without new safety 
concerns compared with its monotherapy components and was well tolerated, similar to 
the monotherapies. It should be noted that the population for the SYNERGY study was 
large and adequately powered, and was also clinically relevant (comprising only wet 
patients; a more severe group), but was otherwise very comparable with populations of 
previous mirabegron monotherapy studies. In addition, the monotherapies performed as 
expected, and the results of multiple outcome parameters (both subjective and objective) 
all indicated improvements with combination therapy compared with monotherapy. The 
most relevant OAB symptom ² urgency and incontinence episodes ² were improved in 
the combination vs monotherapy groups. 
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Table and Figure legends 
 
Table 1 Patient demographic and other baseline characteristics (Safety Analysis Set).  
BMI = body mass index; M = mirabegron; S = solifenacin; SD = standard deviation; UI = 
urgency incontinence.  
* n = 422;  n = 3397. 
 
Table 2 Responders for zero incontinence episodes/24h at end of treatment using the last 
3 diary days. 
CI = confidence interval; M = mirabegron; S = solifenacin.  
*P<0.05. 
Odds ratio and P values are from a logistic regression model including treatment group, sex, 
DJHJURXS\HDUVSUHYLRXV2$%PHGLFDWLRQ\HVQRDQGJHRJUDSKLFUHJLRQDV
factors and baseline mean number of incontinence episodes per 24h during the last 3 days 
as a covariate. The two-sided P value is for pairwise comparisons between the 
combination/active group and the corresponding monotherapy/placebo group from the same 
logistic regression model. 
 
Table 3 Responders for micturition frequency normalization at end of treatment. 
CI = confidence interval; M = mirabegron; S = solifenacin.  
*P<0.05. 
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Table 4 Overview of treatment-emergent adverse events (Safety Analysis Set). 
CI = confidence interval; M = mirabegron; S = solifenacin; TEAE = treatment-emergent 
adverse event.  
* Based on a sponsor-defined list of Preferred Terms or Lower Level Terms (urinary retention 
only). 

 Based on Lower Level Terms. 
$ Based on a standardized MedDRA query.  
 
Fig. 1 Patient disposition. 
AE = adverse event 
* Excludes 1 patient who entered the placebo run-in period but did not take placebo run-in 
medication, and did not have end of run-in page provided but was randomized. 
([FOXGHVSDWLHQWVZKRGLGQRWKDYHHQGRIUXQ-in page provided. 
Á,QFOXGHVSDWLHQWZKRHQWHUHGWKHSODFHERUun-in period but did not take placebo run-in 
medication, and did not have end of run-in page provided but was randomized. 
§ Patients from one site were excluded from the SAF and FAS due to protocol non-
compliance. 
¶ Randomized/registered but never received/dispensed study drug. 
 
Fig. 2 Adjusted change from baseline to end of treatment in (A) mean number of 
incontinence episodes/24h, (B) mean number of micturitions/24h, and (C) mean volume 
voided/micturition.  
M = mirabegron; S = solifenacin. 
 
Fig. 3 Forest plot for treatment difference and 95% CI of adjusted change from baseline in 
(A) mean number of incontinence episodes per 24h at EoT by previous medication for 
OAB (yes, no) and (B) micturitions/24h. 
M = mirabegron; S = solifenacin. 
 
Fig. 4 Change in post-void residual volume from baseline to end of treatment.  
 
Table S1 Exclusion criteria. 
ALT = alanine aminotransferase; AST = aspartate aminotransferase; ECG = 
electrocardiogram; GGT = gamma-glutamyl transferase; OAB = overactive bladder; PVR 
= post-void residual; ULN = upper limit of normal; UTI = urinary tract infection.  
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Note: 'XULQJWKHVWXG\LWZDVFRQVLGHUHGWKDWRYHUDOOH[FOXVLRQRIȕ-blockers was overly 
restrictive; therefore the protocol was amended to allRZDOOȕ-blockers. 
 
Table S2 Statistical analysis. 
 
Table S3 Other secondary efficacy variables.  
 
Table S4 Subgroup analyses by use of previous OAB medication.  
 
Fig. S1 Study design.  
 
Fig. S2 Testing procedure for the coprimary and key secondary variables based on the 
micturition diary. 
 
Fig. S3 Forest plots for treatment difference and 95% confidence intervals of adjusted 
change from baseline to end of treatment in (A) mean number of incontinence 
episodes/24h and (B) micturitions/24h.  
ANCOVA = analysis of covariance; FAS = full analysis set; LOCF = last observation carried 
forward; M = mirabegron; PPS = per protocol set; S = solifenacin. 
 
Fig. S4 Adjusted change from baseline in (A) mean number of incontinence episodes/24h 
and (B) micturitions/24h.  
M = mirabegron; S = solifenacin. 
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Table 1 Patient demographic and other baseline characteristics (Safety Analysis Set).  
 Treatment group Total 
(n = 3398)  Placebo (n = 429) 
M 25 mg 
(n = 423) 
M 50 mg 
(n = 422) 
S 5 mg 
(n = 423) 
S + M 25 mg 
(n = 853) 
S + M 50 mg 
(n = 848) 
Sex, n (%) 
   Male 102 (23.8) 96 (22.7) 99 (23.5) 92 (21.7) 197 (23.1) 197 (23.2) 783 (23.0) 
   Female 327 (76.2) 327 (77.3) 323 (76.5) 331 (78.3) 656 (76.9) 651 (76.8) 2615 (77.0) 
Age, years 
   Mean, SD  57.9 (13.0) 56.9 (13.6) 56.7 (13.3) 58.2 (12.8) 57.1 (13.9) 57.6 (13.4) 57.4 (13.4) 
Age group, n (%) 
   \UVn (%) 146 (34.0) 139 (32.9) 131 (31.0) 138 (32.6) 283 (33.2) 285 (33.6) 1122 (33.0) 
   \UVn (%) 38 (8.9) 32 (7.6) 32 (7.6) 35 (8.3) 70 (8.2) 70 (8.3) 277 (8.2) 
Race, n (%) 
       
  White 346 (80.7) 331 (78.3) 336 (79.6) 335 (79.2) 678 (79.5) 680 (80.2) 2706 (79.6) 
  Black/African 
American 
14 (3.3) 17 (4.0) 8 (1.9) 13 (3.1) 34 (4.0) 28 (3.3) 114 (3.4) 
  Asian 60 (14.0) 69 (16.3) 68 (16.1) 66 (15.6) 123 (14.4) 123 (14.5) 509 (15.0) 
  Other 5 (1.2) 4 (0.9) 6 (1.4) 6 (1.4) 15 (1.8) 12 (1.4) 48 (1.4) 
  Unknown 4 (0.9) 2 (0.5) 4 (0.9) 3 (0.7) 3 (0.4) 5 (0.6) 21 (0.6) 
BMI, kg/m2 (SD) 28.72 (6.07) 28.19 (6.76) 28.33 (6.03) 28.46 (5.90)* 28.59 (5.86) 28.60 (5.88) 28.51 (6.03) 
Type of OAB at screening, n (%) 
  UI only 285 (66.4) 267 (63.1) 268 (63.5) 275 (65.0) 561 (65.8) 567 (66.9) 2223 (65.4) 
Mixed stress/UI 
with urgency 
predominant 
144 (33.6) 156 (36.9) 154 (36.5) 148 (35.0) 292 (34.2) 281 (33.1) 1175 (34.6) 
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Duration of wet OAB symptoms (months)  
    Mean (SD) 67.52 (76.02) 69.27 (88.94) 66.78 (80.67) 66.75 (88.76) 68.16 (87.48) 64.34 (81.17) 66.92 (84.03) 
Previous OAB medication, n (%) 
Yes 205 (47.8) 196 (46.3) 195 (46.2) 204 (48.2) 389 (45.6) 388 (45.8) 1577 (46.4) 
Previous treatment with solifenacin, n (%) 
Yes 83 (19.3) 92 (21.7) 96 (22.7) 97 (22.9) 198 (23.2) 201 (23.7) 767 (22.6) 
Previous treatment with mirabegron, n (%) 
Yes 19 (4.4) 18 (4.3) 19 (4.5) 18 (4.3) 27 (3.2) 34 (4.0) 135 (4.0) 
7-day micturition diary baseline characteristics (FAS)  
 
(n = 418) (n = 410) (n = 411) (n = 415) (n = 827) (n = 827) (n = 3308) 
Number of 
incontinence 
episodes/24h, 
mean (SD) 3.41 (3.37) 3.42 (3.40) 3.18 (3.47) 3.58 (3.51) 3.22 (3.17) 3.16 (3.08) 3.29 (3.29) 
Number of 
micturitions/24h, 
mean (SD) 10.97 (2.86) 10.81 (2.63) 11.19 (3.27) 10.76 (2.47) 10.73 (2.88) 10.74 (2.36) 10.84 (2.73) 
 
(n = 414) (n = 407) (n = 409) (n = 413) (n = 823) (n = 824) (n = 3290) 
Mean volume 
voided in mL, 
mean (SD)  157.94 (58.78) 152.46 (60.96) 155.31 (60.78) 151.94 (59.29) 159.32 (58.29) 153.57 (59.67) 155.43 (59.49) 
 
(n = 415) (n = 407) (n = 405) (n = 414) (n = 823) (n = 822) (n = 3286) 
Number of 
urgency 
incontinence 3.14 (3.23) 3.00 (3.09) 2.89 (3.31) 3.23 (3.34) 2.85 (2.81) 2.80 (2.64) 2.94 (3.00) 
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episodes/24h, 
mean (SD) 
 
(n = 417) (n = 409) (n = 411) (n = 415) (n = 827) (n = 826) (n = 3305) 
Number of 
urgency (Grade 3 
or 4) 
episodes/24h, 
mean (SD) 6.52 (4.05) 6.22 (3.89) 6.46 (4.88) 6.48 (3.88) 6.22 (3.70) 6.22 (3.56) 6.32 (3.92) 
 
(n = 368) (n = 344) (n = 356) (n = 352) (n = 710) (n = 704) (n = 2834) 
Number of 
nocturia 
episodes/24h, 
mean (SD) 1.57 (1.06) 1.53 (1.02) 1.59 (1.09) 1.59 (0.96) 1.56 (1.07) 1.52 (0.97) 1.56 (1.03) 
BMI = body mass index; M = mirabegron; S = solifenacin; SD = standard deviation; UI = urgency incontinence.  
* n = 422;  n = 3397. 
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Table 2 Responders for zero incontinence episodes/24h at end of treatment using the last 3 diary days. 
 Treatment group 
 
Placebo 
(n = 412) 
M 25 mg 
(n = 409) 
M 50 mg 
(n = 406) 
S 5 mg 
(n = 413) 
S + M 25 mg 
(n = 823) 
S + M 50 mg 
(n = 816) 
Responders (%) 155 (37.6) 166 (40.6) 188 (46.3) 177 (42.9) 417 (50.7) 426 (52.2) 
Difference vs S, %  
NA 
7.8 9.3 
95% CI (%) (1.9, 13.7) (3.5, 15.2) 
Odds ratio vs S 
NA 
1.31 1.40 
95% CI (%) (1.02, 1.69) (1.09, 1.81) 
P value 0.035* 0.009* 
Difference vs M, % 
 
NA 
10.1 5.9 
95% CI (%) (4.2, 15.9) (0.0, 11.8) 
Odds ratio vs M  
NA 
 
1.50 1.34 
95% CI (%) (1.16, 1.93) (1.04, 1.73) 
P value 0.002* 0.023* 
Difference vs 
placebo, %  
NA 
3.0 8.7 5.2 13.0 14.6 
95% CI (%) (±3.7, 9.6) (1.9, 15.4) (±1.4, 11.9) (7.3, 18.8) (8.8, 20.4) 
Odds ratio vs 
placebo 
NA 
1.17 1.40 1.34 1.75 1.87 
95% CI (%) (0.87, 1.57) (1.04, 1.87) (0.99, 1.79) (1.36, 2.26) (1.45, 2.42) 
P value 0.300 0.027* 0.055 <0.001* <0.001* 
CI = confidence interval; M = mirabegron; S = solifenacin.  
*P<0.05. 
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Odds ratio and P values are from a logistic regression model including treatment group, sex, age group (<65, 65 years), previous OAB 
medication (yes, no) and geographic region as factors and baseline mean number of incontinence episodes per 24h during the last 3 days as a 
covariate. The two-sided P value is for pairwise comparisons between the combination/active group and the corresponding 
monotherapy/placebo group from the same logistic regression model. 
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Table 3 Responders for micturition frequency normalization at end of treatment.  
 Treatment group 
 
Placebo 
(n = 412) 
M 25 mg 
(n = 409) 
M 50 mg 
(n = 406) 
S 5 mg 
(n = 413) 
S + M 25 mg 
(n = 823) 
S + M 50 mg 
(n = 816) 
Responders (%) 128 (31.1) 172 (42.1) 163 (40.1) 186 (45.0) 422 (51.3) 429 (52.6) 
Difference vs S, %  
NA 
6.2 7.5 
95% CI (%) (0.4, 12.1) (1.6, 13.4) 
Odds ratio vs S 
NA 
1.30 1.43 
95% CI (%) (1.01, 1.67) (1.11, 1.84) 
P value 0.044* 0.006* 
Difference vs M, % 
 
NA 
9.2 12.4 
95% CI (%) (3.3, 15.1) (6.6, 18.3) 
Odds ratio vs M  
NA 
 
1.47 1.60 
95% CI (%) (1.13, 1.90) (1.23, 2.08) 
P value 0.004* <0.001* 
Difference vs 
placebo, %  
NA 
11.0 9.1 14.0 20.2 21.5 
95% CI (%) (4.4, 17.5) (2.5, 15.6) (7.4, 20.5) (14.6, 25.8) (15.9, 27.1) 
Odds ratio vs 
placebo 
NA 
1.66 1.67 1.87 2.43 2.67 
95% CI (%) (1.22, 2.25) (1.23, 2.27) (1.38, 2.54) (1.86, 3.18) (2.04, 3.49) 
P value 0.001* 0.001* < 0.001* < 0.001* < 0.001* 
CI = confidence interval; M = mirabegron; S = solifenacin.  
*P<0.05. 
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Odds ratio and P values are from a logistic regression model including treatment group, sex, age group (<65, 65 years), previous OAB 
medication (yes, no) and geographic region as factors and baseline mean number of micturitions per 24h during the last 3 days as a covariate. 
The two-sided P value is for pairwise comparisons between the combination/active group and the corresponding monotherapy/placebo group 
from the same logistic regression model. 
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Table 4 Overview of treatment-emergent adverse events (Safety Analysis Set).  
 Treatment group 
n (%)  Placebo 
(n = 429) 
M 25 mg 
(n = 423) 
M 50 mg 
(n = 422) 
S 5 mg 
(n = 423) 
S + M 25 mg 
(n = 853) 
S + M 50 mg 
(n = 848) 
TEAEs 145 (33.8) 135 (31.9) 147 (34.8) 149 (35.2) 345 (40.4) 314 (37.0) 
Drug-related TEAEs 45 (10.5) 37 (8.7) 52 (12.3) 63 (14.9) 157 (18.4) 150 (17.7) 
Serious TEAEs 8 (1.9) 6 (1.4) 5 (1.2) 3 (0.7) 12 (1.4) 19 (2.2) 
Drug-related serious TEAEs 0 1 (0.2) 1 (0.2) 0 2 (0.2) 3 (0.4) 
TEAEs leading to permanent 
discontinuation of study drug 
9 (2.1) 7 (1.7) 10 (2.4) 7 (1.7) 20 (2.3) 22 (2.6) 
Drug-related TEAEs leading to 
permanent discontinuation of study drug 
7 (1.6) 4 (0.9) 6 (1.4) 5 (1.2) 17 (2.0) 19 (2.2) 
Urinary tract infection, n (%)* 21 (4.9) 18 (4.3) 16 (3.8) 21 (5.0) 60 (7.0) 44 (5.2) 
   95% CI (2.9, 6.9) (2.3, 6.2) (2.0, 5.6) (2.9, 7.0) (5.3, 8.8) (3.7, 6.7) 
Urinary retention n (%)* 0 0 0 3 (0.7) 8 (0.9) 10 (1.2) 
   95% CI    (0.0, 1.5) (0.3, 1.6) (0.5, 1.9) 
      Urinary retention, n (%) 0 0 0 1 (0.2) 4 (0.5) 5 (0.6) 
      95% CI    (0.0, 0.7) (0.0. 0.9) (0.1, 1.1) 
      Acute urinary retention, n (%) 0 0 0 0 0 1 (0.1) 
      95% CI      (0.0, 0.3) 
      Increased residual urine volume, n 
(%) 0 0 0 0 3 (0.4) 3 (0.4) 
     95% CI     (0.0, 0.7) (0.0, 0.8) 
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      Residual urine  0 0 0 0 1 (0.1) 0 
      95% CI     (0.0, 0.3)  
      Incomplete bladder emptying 0 0 0 1 (0.2) 1 (0.1) 0 
      95% CI    (0.0, 0.7) (0.0, 0.3) 0 
Hypersensitivity reactions n (%)$ 4 (0.9) 4 (0.9) 4 (0.9) 3 (0.7) 9 (1.1) 4 (0.5) 
   95% CI (0.0, 1.8) (0.0, 1.9) (0.0, 1.9) (0.0, 1.5) (0.4, 1.7) (0.0, 0.9) 
Glaucoma n (%)$ 0 1 (0.2) 0 0 1 (0.1) 1 (0.1) 
   95% CI  (0.0, 0.7)   (0.0, 0.3) (0.0, 0.3) 
Somnolence n (%)* 11 (2.6) 11 (2.6) 15 (3.6) 12 (2.8) 29 (3.4) 13 (1.5) 
    95% CI (1.1, 4.1) (1.1, 4.1) (1.8, 5.3) (1.3, 4.4) (2.2, 4.6) (0.7, 2.4) 
Common antimuscarinic TEAEs* 
Dry mouth* 8 (1.9) 17 (4.0) 14 (3.3) 25 (5.9) 74 (8.7) 61 (7.2) 
Blurred vision* 3 (0.7) 1 (0.2) 0 2 (0.5) 5 (0.6) 6 (0.7) 
Constipation* 6 (1.4) 6 (1.4) 11 (2.6) 6 (1.4) 38 (4.5) 31 (3.7) 
Dyspepsia* 3 (0.7) 1 (0.2) 1 (0.2) 1 (0.2) 10 (1.2) 16 (1.9) 
CI = confidence interval; M = mirabegron; S = solifenacin; TEAE = treatment-emergent adverse event.  
* Based on a sponsor-defined list of Preferred Terms or Lower Level Terms (urinary retention only). 

 Based on Lower Level Terms. 
$ Based on a standardized MedDRA query.  
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